# NAD+ Research: Mechanism, Precursor Trials, and Clinical Evidence > NAD+ mechanism of action — sirtuins, PARP1, CD38 — and clinical trial data on NMN, NR, and IV infusion. Peer-reviewed citations throughout. ## NAD+ Mechanism of Action: Sirtuins, PARP, and CD38 NAD+ is the electron carrier at the center of cellular metabolism. In glycolysis, it accepts a hydride ion at the GAPDH step, generating NADH. In the TCA cycle, three additional NADH molecules are produced per acetyl-CoA turn. NADH then donates electrons to Complex I of the mitochondrial electron transport chain, driving the proton gradient that powers ATP synthase. Beyond energy metabolism, NAD+ is a consumed substrate for three enzyme superfamilies: **Sirtuins (SIRT1–7).** NAD+-dependent protein deacylases that remove acyl marks from histones and non-histone proteins, directly linking NAD+ availability to epigenetic regulation and mitochondrial biogenesis. SIRT1 participates in circadian NAD+ recycling: CLOCK:BMAL1 drives rhythmic NAMPT expression, and SIRT1 is recruited to the NAMPT promoter as a feedback amplifier [14]. **PARPs.** PARP1 and PARP2 detect DNA strand breaks and consume NAD+ to poly-ADP-ribosylate target proteins, recruiting repair machinery. Severe DNA damage can deplete up to 90% of cellular NAD+ in minutes [13]. **CD38.** Cleaves NAD+ and NMN to produce ADP-ribose and cyclic ADP-ribose for calcium signaling. CD38 expression rises 2–3-fold with aging (Camacho-Pereira et al. 2016, Cell Metabolism) [1]. Inflammatory SASP cytokines from senescent cells activate CD38-expressing macrophages in visceral fat and liver [2]. ## Why Is NAD+ Central to Cellular Metabolism? Without adequate NAD+, the GAPDH step in glycolysis stalls; the NAD+/NADH redox ratio shifts unfavorably; and mitochondrial ATP synthesis, sirtuin-dependent gene regulation, and PARP-dependent DNA repair all suffer simultaneously — because all three functions draw from the same depleted pool. A circadian dimension compounds this: the CLOCK:BMAL1 complex drives rhythmic NAMPT expression, so NAD+ availability follows a 24-hour cycle [14]. ## Sirtuins and NAD+: The Longevity Enzyme Connection Sirtuins (SIRT1–7) are NAD+-dependent deacylases regulating mitochondrial biogenesis, inflammation response, and DNA repair coordination. NAD+ is consumed in each catalytic cycle; sirtuin activity is a direct readout of cellular NAD+ availability. In the NAD+/PARP1/SIRT1 competition model, dietary supplementation with NAD+ precursors re-activates sirtuin signaling in mouse models of aging and improves mitochondrial function [13]. ## NAD+ and DNA Repair: The PARP Connection PARP1 is the primary sensor of DNA strand breaks. When activated, it can consume 90% of cellular NAD+ within minutes [13]. In human skin biopsies, NAD+ levels declined with age while PARP activity rose; the two correlated inversely — the first direct human tissue evidence for PARP-driven NAD+ depletion in aging [22]. In Werner syndrome patients (52-week RCT, n=9) using 500–1000 mg/day NR, ~140% plasma NAD+ increase was achieved with improved arterial stiffness, HDL counts, and kidney function [21]. ## NMN vs NR: Comparing NAD+ Precursors in Human Studies **NMN** is absorbed via the Slc12a8 sodium-dependent transporter. Its expression increases in aged mouse ileum, potentially compensating for declining NMN bioavailability with age [15]. **NR** enters cells through nucleoside transporters and requires one additional phosphorylation step. At 100–1000 mg/day over 8 weeks, NR raised whole-blood NAD+ by 22%, 51%, and 142% respectively, with no flushing and no serious adverse events at any dose [8]. A 2026 Nature Metabolism four-arm RCT (Christen et al.) directly compared NR, NMN, and nicotinamide (NAM) vs placebo over 14 days: NR and NMN each approximately doubled blood NAD+ vs placebo (differences ~49 µM and ~43 µM respectively; p<0.001), while NAM had no significant effect [16]. ## Nicotinamide Riboside (NR): An NAD+ Precursor in Human Trials NR is a legal dietary supplement in the US (unlike NMN, which FDA classified as a drug ingredient in January 2023). The NR-SAFE trial (Berven et al. 2023) administered 3000 mg/day to Parkinson disease patients for 30 days — no moderate or severe adverse events were reported [18]. In older adults with mild cognitive impairment, 1 g/day NR for 10 weeks raised blood NAD+ 2.6-fold but did not significantly improve cognitive performance [20]. ## Oral NAD+ Bioavailability Oral NAD+ itself is largely hydrolyzed by intestinal NADases (CD38, CD73) before reaching systemic circulation. NMN and NR are the effective oral delivery vehicles. New 2026 evidence (Christen et al.) shows gut microbiome bacteria convert a portion of NR and NMN to nicotinic acid, introducing variability in individual responses [16]. ## Is NAD+ Just Vitamin B3? No. Niacin (nicotinic acid, vitamin B3) is one biosynthetic precursor to NAD+ via the Preiss-Handler pathway, but NAD+ is a dinucleotide coenzyme with molecular formula C₂₁H₂₇N₇O₁₄P₂ and molecular weight 663.4 Da — more than four times the molecular weight of niacin (123.1 Da). ## NAD+ vs NADH NAD+ and NADH are the oxidized and reduced forms of the same molecule. Therapeutic literature focuses on raising the total NAD+ pool — sirtuin activity depends on NAD+ availability, not on the redox ratio per se. --- Chrome-console readings of the peer-reviewed NAD+ record — clinical trials indexed, infusion rates logged, no prescriptions filled.